Immunome Q2 Loss Widens to $73.1M; Cash Drops to $520M, PDUFA Date Set for April 2027

summarizeSummary

Immunome posted a $73.1M net loss for Q2, a steeper deficit than the prior quarter, while cash slipped to $520M. The FDA scheduled an April 2027 PDUFA date for varegacestat, and dosing commenced in two new Phase 1 studies.

check_boxKey Events · Earnings and Guidance · IMNM

• Q2 Net Loss Widens to $73.1M

  Driven by higher R&D expenses of $59.9 million and G&A of $18.3 million, the net loss grew to $73.1 million from $53.8 million in Q1 2026.

• Cash Position Declines to $520M

  Cash, equivalents, and marketable securities dropped to $520.0 million as of June 30, 2026, down from $582.7 million at March 31, 2026. Management projects the runway will extend into 2028.

• Varegacestat PDUFA Date Set for April 28, 2027

  Following positive Phase 3 RINGSIDE data presented at ASCO, the FDA accepted the NDA for varegacestat in desmoid tumors and assigned a target action date of April 28, 2027.

• Two New Phase 1 Trials Initiated

  Dosing began for IM-1617 (ADC) in June 2026 and for IM-3050 (radioligand therapy) in July 2026, both targeting advanced solid tumors.

auto_awesomeAnalysis · IMNM · Life Sciences

A widening quarterly loss and declining cash reserves underscore the cost of advancing Immunome's pipeline, yet the company retains a runway into 2028. The net loss deepened to $73.1 million from $53.8 million in Q1, fueled by a ramp in R&D spending. Cash fell to $520 million from $582.7 million, a burn rate that remains manageable for a pre-commercial biotech. On the regulatory front, the FDA accepted the varegacestat NDA and set a PDUFA date of April 28, 2027, marking a pivotal milestone. Meanwhile, first patients were dosed in Phase 1 trials for IM-1617 and IM-3050, broadening the clinical footprint.